Inhibitory potency of Valsartan/Sacubitril drug combination: molecular docking simulations

被引:0
|
作者
Jovanovic, Jelena Dorovic [1 ,2 ]
Markovic, Zoran [2 ]
Kokanovic, Mihajlo [1 ]
Filipovic, Nenad [3 ]
Stanojevic, Ma Rijana [4 ]
机构
[1] Bioengn Res & Dev Ctr BioIRC, Kragujevac, Serbia
[2] Univ Kragujevac, Inst Informat Technol, Dept Sci, Kragujevac 34000, Serbia
[3] Univ Kragujevac, Fac Engn, Bioengn Res & Dev Ctr, Kragujevac, Serbia
[4] Univ Kragujevac, Fac Med Sci, Pirkov Dept Biochem, Kragujevac 34000, Serbia
基金
欧盟地平线“2020”;
关键词
Entresto; molecular docking simulations; Neprilysin; Angiotensin II receptor;
D O I
10.1109/BIBE52308.2021.9635185
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Heart failure (HF) is a condition that affects mostly older populations. It can be treated with different medications, and one of them is Entresto. This is a medication which is consisting of two drugs, sacubitril (SAC) and valsartan (VAL). Here, in this study, are performed molecular docking simulations in order to examine the inhibitory potency of SAC and VAL towards neprilysin (NEP) and angiotensin II receptor (AT2), respectively. The achieved thermodynamic parameters shows that SAC and VAL can bind to targeted protein, and inhibit NEP and AT2. The best binding sites are determined. Also, the amino acids responsible for binding are identified.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Sacubitril/valsartan: An antiarrhythmic drug?
    Huang, Elaine
    Bernard, Michael L.
    Hiltbold, A. Elise
    Khatib, Sammy
    Polin, Glenn M.
    Rogers, Paul A.
    Dominic, Paari
    Morin, Daniel P.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2022, 33 (11) : 2375 - 2381
  • [2] Sacubitril/Valsartan and Mexiletine: A Proarrhythmic Combination?
    Weir, Robin A. P.
    CARDIOLOGY, 2019, 142 (01) : 4 - 6
  • [3] Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
    Sarrias, Axel
    Bayes-Genis, Antoni
    CIRCULATION, 2018, 138 (06) : 551 - 553
  • [4] Sacubitril/Valsartan A Novel Cardiovascular Combination Agent
    Sible, Alexandra M.
    Nawarskas, James J.
    Alajajian, David
    Anderson, Joe R.
    CARDIOLOGY IN REVIEW, 2016, 24 (01) : 41 - 47
  • [5] A Drug Utilization Study of Sacubitril/Valsartan in Catalonia
    Molina, Andrea
    Vicente, Montse
    Gasol, Montse
    Carbonell, Pere
    Lopez, Pilar
    Pontes, Caridad
    REVISTA ESPANOLA DE CARDIOLOGIA, 2019, 72 (07): : 593 - 595
  • [6] Sacubitril/valsartan: a cardiovascular drug with pluripotential actions
    Chrysant, Steven G.
    Chrysant, George S.
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2018, 8 (04) : 543 - 548
  • [7] Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
    Mustafa, Nor Hidayah
    Jalil, Juriyati
    Zainalabidin, Satirah
    Saleh, Mohammed S. M.
    Asmadi, Ahmad Yusof
    Kamisah, Yusof
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update
    Nielsen, Peter Munch
    Grimm, Daniela
    Wehland, Markus
    Simonsen, Ulf
    Krueger, Marcus
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 9 - 18
  • [10] Effect of sacubitril/valsartan combination in an experimental model of heart failure
    De Angelis, Antonella
    Cappetta, Donato
    Telesca, Marialucia
    Bellocchio, Gabriella
    Urbanek, Konrad
    Berrino, Liberato
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)